WallStreetZenWallStreetZen

NASDAQ: AGMB
Agomab Therapeutics Nv Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Agomab Therapeutics Nv revenue was $0.00 for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $0.0, down N/A from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, AGMB annual revenue was $0.0, with N/A growth year-over-year.

AGMB revenue history

Current Revenue
$0.0
Current Earnings
-$73.6M
Current Profit Margin
0%

Be the first to know when AGMB announces revenue.

AGMB Revenue History By Year

AGMB Yearly RevenueAGMB RevenueAGMB ChangeAGMB Revenue Growth
2025-12-31$0.00N/AN/A
2024-12-31$0.00N/AN/A
2023-12-31$0.00N/AN/A

1 of 1

Agomab Therapeutics Nv Revenue FAQ

What was AGMB's revenue last quarter?

Agomab Therapeutics Nv (NASDAQ: AGMB) reported Q4 2025 revenue of $0.00 up N/A year over year. In the same quarter last year, Agomab Therapeutics Nv's revenue was $0.00.

What was Agomab Therapeutics Nv's revenue in 2025?

Agomab Therapeutics Nv's annual revenue for the twelve months ending Dec 31, 2025 was $0.00, a N/A decrease year over year.

How much does Agomab Therapeutics Nv make in a day?

Based on Agomab Therapeutics Nv annual revenue for the past two years, AGMB makes an average of $0.00 per day.

What was Agomab Therapeutics Nv's annual revenue growth in the past year?

As of Q2 2026, Agomab Therapeutics Nv's revenue has grown null year over year. Agomab Therapeutics Nv's revenue in the past year totaled $0.00.

How much does Agomab Therapeutics Nv make in a year?

Agomab Therapeutics Nv's revenue by year for the past two years is:
  • Agomab Therapeutics Nv's revenue for the twelve months ending Dec 31, 2025 was $0.00, a N/A decrease year over year.
  • Agomab Therapeutics Nv's annual revenue for Dec 31, 2024 was $0.00, a N/A decrease from 2023.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.